ABK Biomedical, Inc. announced the first patient treated in ABK’s First-in-Human study with Eye90 microspheres™, a Y90 radioembolization device for the treatment of liver cancers. This study is being conducted in collaboration with Auckland Hospital Research Unit, New Zealand. The prospective, single-center, open-label study is evaluating the safety and effectiveness of Eye90 microspheres in patients…
eTurboNews Artiklene er kun for abonnenter. Abonnement er GRATIS.
Abonnenter logger inn her Klikk her for å abonnere GRATIS
Abonnenter logger inn her Klikk her for å abonnere GRATIS
HVA SKAL TA BORT FRA DENNE ARTIKKELEN:
- announced the first patient treated in ABK’s First-in-Human study with Eye90 microspheres™, a Y90 radioembolization device for the treatment of liver cancers.
- This study is being conducted in collaboration with Auckland Hospital Research Unit, New Zealand.
- The prospective, single-center, open-label study is evaluating the safety and effectiveness of Eye90 microspheres in patients….
